TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Cequa™ in Subjects With Dry Eye Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female subjects with a history of bilateral dry eye disease for a period of at least 3 months.~2. Aged of at least 18 years.~3. Subjects with total corneal fluorescein staining ≥6 or corneal fluorescein staining in an individual zone ≥2 as per National Eye Institute Grading Scale.~4. Subjects with modified symptom assessment in dry eye global symptom score, ≥40 using visual analogue scale.~5. Subjects with best-corrected visual acuity 20/200 or better in both eyes at the Screening/Baseline visit~Exclusion Criteria:~1. Subjects who have used cyclosporin 0.05% ophthalmic emulsion in both eyes for less than 3 months prior to the Screening/Baseline visit.~2. Subjects with history of treatment failure with cyclosporin 0.05% ophthalmic emulsion.~3. Subjects who have active seasonal and/or perennial allergic conjunctivitis in either eye.~4. Subjects who had already Use initiated any systemic or topical ocular medication.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CequaTM (Cyclosporine 0.09%) ophthalmic solution (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Interaction of Flavor With Nicotine Form in Adult Smokers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 21 years old, able to read and write, use of combustible~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- E-cigarette flavor (Type: EXPERIMENTAL): In this arm, participants will receive two experimental e-cigarette flavors
- E-cigarette nicotine form (Type: EXPERIMENTAL): In this arm, participants will receive two forms of nicotine in an e-cigarette

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients Not Adequately Responding to Aliskiren Alone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed patients or patients who have not been treated for hypertension within the 4 weeks prior to Visit 1 must have a mean sitting Diastolic Blood Pressure (msDBP) ≥ 95 mmHg and \< 110 mmHg at Visits 1 and 2~* Patients who have been treated for hypertension within the 4 weeks prior to - Visit 1 must have a msDBP ≥ 90 mmHg and \< 110 mmHg at Visit 2~* All patients must have a msDBP ≥ 90 mmHg and \< 110 mmHg at Visit 4~Exclusion Criteria:~* Severe hypertension~* Pregnant or nursing (lactating) women~* Women of child-bearing potential~* Previous or current diagnosis of heart failure New York Heart Association (NYHA Class II-IV)~* Serum potassium ≥ 5.3 mEq/L (mmol/L) at Visit 1~* Uncontrolled Type 1 or Type 2 diabetes mellitus~* Hypersensitivity to renin inhibitors, calcium channel blockers, or to drugs with Similar chemical structures~* History of hypertensive encephalopathy or cerebrovascular accident, or history of transient ischemic attack (TIA), myocardial infarction, coronary bypass surgery, or any percutaneous coronary intervention~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aliskiren 300 mg/Amlodipine 5 mg (Type: EXPERIMENTAL): Participants received 1 Aliskiren/Amlodipine 300/5mg tablet + 1 Placebo to Aliskiren tablet once daily in the morning for 8 weeks.
- Aliskiren 300 mg/Amlodipine 10 mg (Type: EXPERIMENTAL): Participants received 1 Aliskiren/Amlodipine 300/10 mg tablet + 1 Placebo to Aliskiren tablet orally once daily in the morning for 8 weeks.
- Aliskiren 300 mg (Type: ACTIVE_COMPARATOR): Participants received 1 Aliskiren 300 mg tablet + 1 Placebo to Aliskiren/Amlodipine tablet orally once daily in the morning for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Intervention to Empower HIV Clients as Prevention Advocates in Uganda

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria (People living with HIV):~* 18+ years old~* In HIV care for \> 1 year~* Having disclosed serostatus to at least one person~Inclusion Criteria (Social network members):~* 18+ years old~* Referred by a patient participant because they are family members, friends, or other people in patients' social network~* knows patient participant's serostatus~Exclusion Criteria:~* Individuals who meet the inclusion criteria above will be eligible to participate, and no other exclusion criteria apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Game Changers Intervention (Type: EXPERIMENTAL): Game Changers is an intervention that aims to empower and mobilize people living with HIV to be agents for HIV prevention and behavioral change in their social networks.
- Control (Type: NO_INTERVENTION): The control group will receive standard of care during the intervention assessment period. All control participants will be offered the Game Changers program once all assessments for the primary study outcomes have been completed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Longitudinal Antimalarial Combinations in Uganda

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Phase I~* Age 1 to 10 years.~* Agreement to come to the study clinic for any febrile episode or other illness.~* Agreement to avoid medications administered outside the study.~* Willingness of parents or guardians to provide informed consent.~Phase II~* Child and Guardian/Parent belong to household currently enrolled in the study.~* Age 1 to 10 years.~* Agreement to come to the study clinic for any febrile episode or other illness.~* Agreement to avoid medications administered outside the study.~* Willingness of parents or guardians to provide informed consent.~Exclusion Criteria:~Phase I~* History (obtained from the parent/guardian) of any known serious chronic disease requiring frequent medical care (e.g. AIDS, sickle cell disease, malignancy).~* Intention to move from Kampala during the follow-up period.~* History (obtained from the parent/guardian) of serious side effects to study medications or sulfa drugs.~* Weight \< 10 kg~* Severe malnutrition defined as weight-for-height or height-for-age Z-score \<-3.~* Homozygous hemoglobin SS (sickle cell) result by hemoglobin electrophoresis.~* Life-threatening screening laboratory value in the absence of malaria:~* Absolute neutrophil count: \< 250/mm\^3~* Hemoglobin: \< 5.0 g/dL~* Platelet count: \< 25,000/mm\^3~* Creatinine: \< 2 years: \> 1.5 mg/dL, greater than or equal to 2 years: \> 2.0 mg/dL~* ALT: \> 15.0 x ULN~* Bilirubin: \> 7.5 x ULN Phase II~* History of any known serious chronic disease requiring frequent medical attention (e.g. AIDS, sickle cell disease, malignancy)~* Intention to move from Kampala during the follow-up period~* Any history of serious side effects to study medications~* Weight \< 10 kg~* Severe malnutrition~* Life-threatening screening laboratory test result

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 10 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of the Efficacy and Safety of Two Homologous Active Principles for Local Dental Anesthesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy men and women, criteria assessed during anamnesis~* Age between 18 and 25 years old~* Presence of lower third molars in the mouth with no level of eruption determined by the clinical oral examination~* Weight / height ratio with a coefficient of variation of no more than 15% of the ideal weight, according to the tables of the Metropolitan Life Insurance~* Lower third molars in a mesio-angulated position evidenced by the panoramic radiography taken for the study in the Faculty of Dentistry of the University of Antioquia, and which is in Nolla's stage equal or greater than 6~* Voluntary acceptance to participate in the study by signing the informed consent~Exclusion Criteria:~* Presence of phobias or traumas related to the dental practice and/or with needles~* Presence of clinical problems such as kidney diseases, cardiovascular diseases, known allergies or drug hypersensitivity discovered through the anamnesis of the clinical history prepared for the investigation~* Hi consumption of alcohol or cigarettes~* Presence of problems related to drug dependence~* Being ill for the last two weeks before the study begins~* use of enzyme inhibitors or inducers for four weeks prior to the participation in the study~* Have used any medication or natural product, seven days prior to the first part of the study~* Have donated blood in the last three months~* Have participated in another clinical trial, thirty days prior to the first part of the study~* Be a member of the research group or a relative of the responsible personnel involved in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 22 Years
- Healthy Volunteers: t

Study Arms:
- NS Lower right molar (Type: EXPERIMENTAL): IANB Artheek SP Articaine EPINEPHrine Cartridge 4% 1:100000
- SD Lower Left molar (Type: ACTIVE_COMPARATOR): IANB Septanest Articaine EPINEPHrine Cartridge 4% 1:100000
- NS Lower left molar (Type: EXPERIMENTAL): IANB Artheek SP Articaine EPINEPHrine Cartridge 4% 1:100000
- SD Lower right molar (Type: ACTIVE_COMPARATOR): IANB Septanest Articaine EPINEPHrine Cartridge 4% 1:100000

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Budesonide-Formoterol in Bronchiectasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18-80 years old patients diagnosed of non-cystic fibrosis bronchiectasis~* More than 1 pulmonary lobe affected~* Chronic obstructive airflow obstruction~* Stable phase of the disease~Exclusion Criteria:~* Asthma, COPD or current/past smnokers~* No consent~* Known intolerance to budesonide or formoterol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Medium Dose of budesonide-formoterol
- B (Type: ACTIVE_COMPARATOR): High dose of inhaled budesonide (1600 mcg/day)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open-trial on the Prevention of Chronic Migraines With the CEFALY Device

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a history of chronic migraine meeting the diagnostic criteria listed in ICHD-III beta (2013) section 1, migraine (1), with the exception of ''complicated migraine'' (i.e., hemiplegic migraine, migraine with brainstem aura, ophthalmoplegic migraine-recurrent painful ophthalmoplegic neuropathy, migrainous infarction) will be enrolled. They are required during baseline to have ≥15 headache days with each day consisting of ≥4 hours of continuous headache and with ≥50% of days being migraine or probable migraine days; and ≥4 distinct headache episodes, each lasting ≥4 hours.~Both patients with or without acute medication overuse (medication overuse headache - MOH) will be recruited~Exclusion Criteria:~1. Women: Pregnant, lactating or \<6 months post partum~2. For patients already on treatment with medications in the following classes: antihypertensives, antidepressants, antiepileptics, no dose change of those medications is allowed for at least 3 months before start of baseline and during the entire study period.~3. For patients treated with Botox, no injection within 4 months before start of baseline or during the study.~4. Diagnosis of other primary or secondary headache disorders, except of Medication Overuse Headache~5. A Beck Depression Inventory score of \>24 at baseline~6. Psychiatric disorders that could have interfered with study participation~7. Intolerance to supraorbital neurostimulation that makes the treatment not applicable (test of nociceptive threshold with specific Cefaly program)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Active (Type: EXPERIMENTAL): Daily trigeminal nerve stimulation session of 20 minutes with CEFALY

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Eltrombopag and High-dose Dexamethasone as First Line Treatment for IT

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinically confirmed immune thrombocytopenic (IT) Platelet count less than 30,000/mm3 on two occasions. Platelets \>30000/mm3 with bleeding.~* Less than seven days taking corticosteroids~* Normal to increased numbers of megakaryocytes on bone marrow examination in patients ≥ 60 years~* Subject is ≥ 18 years~* Subject has signed and dated written informed consent.~* No sepsis or fever~* No active infection requiring therapy~* No active chronic viral infection~* HIV negative~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~Exclusion Criteria:~* Performance status above or equal to 2.~* Previous treatment with eltrombopag~* Immunosuppressive treatment within the last month~* Previous splenectomy~* Presence of malignant haematological disease~* Connective tissue disease~* Autoimmune hemolytic anemia~* Pregnancy and lactation~* Not willing to participate in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Eltrombopag and dexamethasone (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adolescents and pre-adolescents with no prior sexual history~* Healthy women who have an intact uterus with lifetime history of 0-4 sexual partners~Exclusion Criteria:~* Prior Human Papillomavirus (HPV) vaccination~* Prior abnormal Paps~* Prior history of genital warts

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 23 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): 100% Formulation qHPV Vaccine
- 2 (Type: EXPERIMENTAL): 60% Formulation qHPV Vaccine
- 3 (Type: EXPERIMENTAL): 40% Formulation qHPV Vaccine
- 4 (Type: EXPERIMENTAL): 20% Formulation qHPV Vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Benefix in Patients With Hemophilia B in Usual Care Settings in China

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and/or female subjects with hemophilia B.~* Subjects/parents/legal representatives must be able to comply with study procedures (informed consent/assent process, clinical visits, reporting of infusion and bleed data, reporting of adverse events, etc)~Exclusion Criteria:~* Presence of any other bleeding disorder in addition to hemophilia B. Subjects with a past history of, or current factor IX inhibitor. For laboratory-based assessments, any Bethesda inhibitor titer greater than the laboratory's normal range or ≥0.6 Bethesda Unit (BU)/mL.~* Subjects with known hypersensitivity to the active substance or to any of the excipients of BeneFIX.~* Subjects with a known hypersensitivity to Chinese Hamster Ovary cell proteins.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Benefix (Type: EXPERIMENTAL): This is a single arm study. Subjects will be treated with Benefix by the investigator according to usual care in China and in accord with the China BeneFIX Package Insert.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Functional Respiratory Imaging Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject's signed Informed Consent Form;~2. Male or female ≥ 40 years of age;~3. Current smokers or ex-smokers of at least 10 pack-years,~4. Established diagnosis of COPD~5. Post-BD Forced Expiratory Volume in one second/Forced Vital Capacity (FEV1/FVC) \< 0.7 and FEV1 ≤ 60% of predicted at V1~6. On a stable dose any non-extra fine ICS/LABA DPI twice daily regimen for at least 8 weeks before screening;~7. Presence of lung hyperinflation~8. Symptomatic subjects with COPD assessment test (CAT) score ≥ 10;~9. Documented history of ≥ 1 moderate or severe COPD exacerbation in the previous 12 months~Exclusion Criteria:~1. Pregnant or lactating woman;~2. Exacerbations defined as a sustained and acute deterioration of subject's symptoms and signs 30 days before screening;~3. A current asthma diagnosis;~4. Respiratory disorders other than COPD:~5. Cardiovascular diseases;~6. Evidence or history of other concurrent disease such as but not limited to hyperthyroidism, diabetes mellitus or other endocrine disease;~7. Medical history or current diagnosis of narrow-angle glaucoma;~8. History of lung transplant or lung reduction surgery;~9. ECG criteria: any clinically significant abnormal 12-lead ECG that in the investigator's opinion would affect efficacy or safety evaluation or place the subjects at risk;~10. Laboratory abnormalities;~11. Alcohol/drug abuse;~12. Contra-indications to Investigational medical products (IMPs), based on investigator judgement;~13. Documented Covid-19 diagnosis or its complications which have not resolved within 14 days prior to screening;~15. Positive molecular Covid-19 test within the last 72 hours before the remaining of screening activities.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CHF5993 (Type: EXPERIMENTAL): Beclometasone Dipropionate (BDP) 100 μg/inhalation + Formoterol Fumarate (FF) 6 μg/inhalation + Glycopyrronium Bromide (GB) 12.5 µg/inhalation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Orthopaedic Treatment Proximal Humeral Fractures

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 75 years or older.~* 3 or 4 parts fracture (Neer's Classification).~Exclusion Criteria:~* Comorbilities affecting to functional recovery.~* Fractures associating shoulder dislocation.~* Open fractures including neurovascular damage.~* Polytraumatized patients

- Gender: ALL
- Minimum Age: 75 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Orthopedic treatment (Type: None): This is the prospective cohort which includes 20 patients presenting three-four proximal humeral fracture who were treated non-surgically and followed prospectively during 12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete